|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|||||||||||
| 化学式 | C29H23N7O2S2 |
||||||||||||||
| 分子量 | 565.67 | CAS No. | 913822-46-5 | ||||||||||||
| Solubility (25°C)* | 体外 | DMSO (warmed with 50ºC water bath) | 35 mg/mL (61.87 mM) | ||||||||||||
| Water | Insoluble | ||||||||||||||
| Ethanol | Insoluble | ||||||||||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||||||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||||||||||
| 製品説明 | SC75741 is a potent NF-κB inhibitor with EC50 of 200 nM. SC75741 efficiently blocks influenza virus propagation. |
|---|---|
| in vitro | SC75741 shows immunosuppressive activity by inhibiting human PBMC proliferation with IC50 of 2.2 μM. [1] This compound inhibits replication of influenza A and B viruses by inhibiting NF-κB-mediated signalling on a transcriptional level. Moreover, it shows a high barrier for development of resistant virus variants. [2] |
| in vivo | SC75741 (15 mg/kg i.p.) reduces virus replication and cytokine expression in mice lungs after H5N1 influenza virus infection. [2] |
| 特徴 | NF-κB-selective inhibitor. |
| キナーゼアッセイ | NF-κB reporter gene assay | |
|---|---|---|
| The NF-κB reporter gene assay is prepared with A549-NF-κB-SEAP cell line according to manufacturer’s instructions. In short, A549 cells stably transfected with pNF-κB-SEAP reporter gene plasmid are plated and allowed to attach overnight. The cells are subsequently incubated for 5 h with described compounds at 100, 30, 10, 3, 1, 0.3, 0.1, and 0 μM and then stimulated with 10 ng/ml TNF-α for 22 h. The supernatant of the cell is analyzed for SEAP activity using a chemiluminescent SEAP reporter gene assay. | ||
| 細胞アッセイ | 細胞株 | Human PBMCs |
| 濃度 | ~50 μM | |
| 反応時間 | 48 hours | |
| 実験の流れ | Cell viability assay is prepared using a CellTiter-BluTM Cell Viability Assay. For each concentration of the compound four replicates are measured. | |
| 動物実験 | 動物モデル | C57BL/6 mice infected with H5N1 influenza virus |
| 投薬量 | ~15 mg/kg | |
| 投与方法 | i.p. | |
|

Data from [Data independently produced by , , Oncotarget, 2016, 7(32):52281-52293]

Data from [Data independently produced by , , J Nutr Biochem, 2016, 41:56-64. ]

Data from [Data independently produced by , , J Nutr Biochem, 2017, 41:56-64]
| Complementary approaches define the metabolic features that accompany Richter syndrome transformation [ Cell Mol Life Sci, 2025, 82(1):152] | PubMed: 40204982 |
| Critical role of the β isoform of protein kinase C (PKCβ) in angiotensin II-induced oxidative stress in vascular smooth muscle cells [ Physiol Rep, 2025, 13(20):e70595] | PubMed: 41103077 |
| Tumor necrosis factor receptor 2 promotes endothelial cell-mediated suppression of CD8+ T cells through tuning glycolysis in chemoresistance of breast cancer [ J Transl Med, 2024, 22(1):672] | PubMed: 39033271 |
| Hepatocyte growth factor enhances the ability of dental pulp stem cells to ameliorate atherosclerosis in apolipoprotein E-knockout mice [ World J Stem Cells, 2024, 16(5):575-590] | PubMed: 38817328 |
| Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of ABCB1 in Non-small Cell Lung Cancer [ Anticancer Res, 2024, 44(12):5271-5282] | PubMed: 39626921 |
| Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth [ J Exp Clin Cancer Res, 2023, 42(1):25] | PubMed: 36670508 |
| A Disintegrin and Metalloproteinase with Thrombospondin Motifs 4 Regulates Pulmonary Vascular Hyperpermeability through Destruction of Glycocalyx in Acute Respiratory Distress Syndrome [ Int J Mol Sci, 2023, 10.3390/ijms242216230] | PubMed: 38003418 |
| Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment [ Nat Commun, 2022, 13(1):4261] | PubMed: 35871223 |
| Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment [ Nat Commun, 2022, 13(1):4261] | PubMed: 35871223 |
| Oocytes could rearrange immunoglobulin production to survive over adverse environmental stimuli [ Front Immunol, 2022, 13:990077] | PubMed: 36405746 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。